Pharmacokinetic Study of Oral and Bolus Intravenous 2-Chlorodeoxyadenosine in Patients with Malignancy

Journal of Clinical Oncology

Volumn 14, Issue 3, 1996, Pages 978-983

  Saven, Alan ^a   Cheung, Wing K ^b   Smith, Ian ^b   Moyer, Michael ^b   Johannsen, Tricia ^b   Rose, Esther ^b   Gollard, Russell ^b   Kosty, Michael ^b   Miller, William E ^b   Piro, Lawrence D ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE;

ADVANCED CANCER; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CLADRIBINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; TREATMENT OUTCOME;

EID: 0029918664     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.3.978     Document Type: Article

References (27)

1. Seto S, Carrera CJ, Kubota M, et al: Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75:377-383, 1985
2. Seto S, Carrera CJ, Wasson DB, et al: Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes. J Immunol 136:2839-2843, 1986
3. Piro LD, Carrera CJ, Carson DA, et al: Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117-1121, 1990
4. Saven A, Piro L: Newer purine analogues for treatment of hairy cell leukemia. N Engl J Med 330:691-697, 1994
5. Estey EM, Kurzrock R, Kantarjian HM, et al: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79:882-887, 1992
6. Tallman MS, Hakimian D, Variakojis D, et al: A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 9:2203-2209, 1992
7. Saven A, Carrera CJ, Carson DA, et al: 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 5:133-138, 1991 (suppl)
8. Juliusson G, Liliemark J: High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 11:679-689, 1993
9. Saven A, Lemon RH, Kosty M, et al: 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 13:570-574, 1995
10. Tallman MS, Hakimian D, Zanzig C, et al: Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 13:983-988, 1995
11. Kay AC, Saven A, Carrera CJ, et al: 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 10:371-377, 1992
12. Saven A, Carrera CJ, Carson DA, et al: 2-Chlorodeoxyadenosine: An active agent in the treatment of cutaneous T-cell lymphoma. Blood 80:587-592, 1992
13. Dimopoulos MA, Kantarjian HM, Estey EH, et al: Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 118:195-198, 1993
14. Hoffman M, Tallman M, Hakimian D, et al: 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 12:788-792, 1994
15. Liliemark J, Albertioni F, Hassan M, et al: On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: Alternative routes of administration. J Clin Oncol 10:1514-1518, 1992
16. Oken MM, Greech LH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
17. Validation data on file. Raritan, NJ, R.W. Johnson Pharmaceutical Research Institute, 1995
18. Carson DA, Wasson DB, Beutler E: Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci USA 81:2232-2236, 1984
19. Akaike A: Posterior probabilities for choosing a regression model. Ann Inst Statist Math 30:A9-A14, 1978
20. Schwarz G: Estimating the dimension of a model. Ann Statist 6:461-464, 1978
21. Saven A, Tallman M, Hakimian D, et al: Treatment of large granular lymphocyte (LGL) leukemia with 2-chlorodeoxyadenosine (2-CdA). Proc Am Soc Clin Oncol 14:1027, 1995 (abstr)
22. Saven A, Piro LD: 2-Chlorodeoxyadenosine: A newer purine analogue active in the treatment of indolent lymphoid malignancies. Ann Intern Med 120:784-791, 1994
23. Liliemark J, Pettersson B, Juliusson G: The relationship between plasma 2′-chloro-2′-deoxyadenosine (CdA) and cellular CdA nucleotides (CdAN) after intermittent and continuous IV infusion in patients with chronic lymphocytic leukemia. Blood 78:123, 1991 (abstr)
24. Juliusson G, Johnson SAN, Christiansen I, et al: Oral 2-chlorodeoxyadenosine (2-CdA) as primary treatment for symptomatic chronic lymphocytic leukemia (CLL). Blood 82:551, 1993 (abstr)
25. Liliemark J, Albertioni F, Pettersson B, et al: Bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine (CdA). Proc Am Soc Clin Oncol 11:112, 1992 (abstr)
26. Kawasaki H, Carrera CJ, Piro LD, et al: Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 81:597-601, 1993
27. Albertioni F, Juliusson G, Liliemark J: On the pharmacokinetics of 2-chloro-2′-deoxyadenosine (CdA); Metabolism of 2-chloroadenine (CAde) and renal excretion after intravenous and oral administration. Proc Am Soc Clin Oncol 13:157, 1994 (abstr)